[Recent Insights into HLA-dependent Idiosyncratic Liver Injury].

Area of Science:

• Immunology
• Pharmacology
• Hepatology

Background:

• Idiosyncratic drug-induced liver injury (iDILI) is a rare, unpredictable adverse drug reaction.
• Traditional toxicological models fail to explain iDILI's unpredictable nature.
• Recent research highlights immune-mediated mechanisms, particularly CD8+ T cell activation.

Purpose of the Study:

• To elucidate the immunological underpinnings of iDILI.
• To shift the understanding of iDILI from a toxicological to an immunological process.
• To explore the role of human leukocyte antigen (HLA) alleles and immune tolerance in iDILI pathogenesis.

Main Methods:

• Review of recent immunological studies on iDILI.
• Analysis of the stepwise T cell activation process in iDILI.
• Discussion of HLA-transgenic mouse models for studying immune responses.

Main Results:

• iDILI involves CD8+ T cell activation restricted by specific HLA class I alleles.
• Breakdowns in immune tolerance (e.g., regulatory T cell dysfunction) are critical.
• Effective T cell activation requires both HLA-mediated antigen presentation (Signal 1) and co-stimulatory signals (Signal 2).

Conclusions:

• iDILI is an immunologically orchestrated process, not purely toxicological.
• A permissive immune environment and specific immune signals are necessary for iDILI.
• HLA-transgenic models aid in investigating HLA-restricted immunity and improving iDILI risk prediction.